LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis
Wu G. et al. 2021. Nature Cancer. 2(11):1170-1184.
Previous
Previous
IO-108, a Fully Human Therapeutic Antibody Blocking the Myeloid Checkpoint LILRB2/ILT4, Promotes Innate and Adaptive Anti-Cancer Immunity in Preclinical Studies
Next
Next